PMID- 35470461
OWN - NLM
STAT- MEDLINE
DCOM- 20220824
LR  - 20220825
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 47
IP  - 8
DP  - 2022 Aug
TI  - Analysis of drug adverse events in elderly patients based on the Japanese Adverse 
      Drug Event Report Database.
PG  - 1264-1269
LID - 10.1111/jcpt.13670 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Compared with the general adult population, 
      pharmacokinetics and changes in drug responsiveness occur to a greater extent in 
      the elderly. Interactions may occur between drugs used in combination to treat 
      various diseases and may cause adverse events (AEs). We conducted a 
      cross-sectional risk assessment of AEs in elderly patients based on information 
      gathered from Japanese medical practices with the goal of obtaining information 
      that will contribute to optimizing pharmacotherapy. METHODS: The Japanese Adverse 
      Drug Event Report database was used to determine the incidence of AEs in elderly 
      patients (aged 80 years or older) compared with patients aged less than 80 years 
      old by evaluating the reporting odds ratio using the data obtained from reports. 
      RESULTS AND DISCUSSION: Hypnotics and anxiolytics, as well as anticoagulants and 
      theophylline, were identified as groups of drugs that warrant special attention 
      in the elderly. Hypnotics and anxiolytics, especially those that are 
      short-acting, tend to cause delirium and geriatric syndromes including falls and 
      fractures. With respect to anticoagulants, no increase in the risk of bleeding 
      was evident and the dose was believed to be properly adjusted; however, there was 
      an increased risk of anemia. Theophylline toxicity tended to occur more 
      frequently in the elderly, suggesting the need for drug monitoring. WHAT IS NEW 
      AND CONCLUSION: Based on these cross-sectional studies, the evaluation of the 
      risk of AEs for drugs commonly used in the elderly based on near real-world 
      information was achieved.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Okada, Akira
AU  - Okada A
AUID- ORCID: 0000-0001-5740-4346
AD  - Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, 
      Nishi-tokyo, Japan.
AD  - Research Institute of Pharmaceutical Sciences, Musashino University, Nishi-tokyo, 
      Japan.
FAU - Sera, Shoji
AU  - Sera S
AD  - Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, 
      Nishi-tokyo, Japan.
AD  - Research Institute of Pharmaceutical Sciences, Musashino University, Nishi-tokyo, 
      Japan.
FAU - Taguchi, Maho
AU  - Taguchi M
AD  - Department of Regulatory Science, Faculty of Pharmacy, Yokohama University of 
      Pharmacy, Yokohama, Japan.
FAU - Yamada, Hiroaki
AU  - Yamada H
AD  - Department of Regulatory Science, Faculty of Pharmacy, Yokohama University of 
      Pharmacy, Yokohama, Japan.
FAU - Nagai, Naomi
AU  - Nagai N
AD  - Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, 
      Nishi-tokyo, Japan.
AD  - Research Institute of Pharmaceutical Sciences, Musashino University, Nishi-tokyo, 
      Japan.
LA  - eng
GR  - 20mk0101159h0002/Japan Agency for Medical Research and Development/
GR  - 19mk0101159h0001/Japan Agency for Medical Research and Development/
PT  - Journal Article
DEP - 20220425
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Hypnotics and Sedatives)
RN  - C137DTR5RG (Theophylline)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anti-Anxiety Agents
MH  - Anticoagulants
MH  - Cross-Sectional Studies
MH  - *Drug-Related Side Effects and Adverse Reactions/epidemiology
MH  - Humans
MH  - Hypnotics and Sedatives
MH  - Japan/epidemiology
MH  - Theophylline
OTO - NOTNLM
OT  - adverse drug event
OT  - database
OT  - direct-acting oral anticoagulants
OT  - elderly
OT  - hypnotics
OT  - sedatives
OT  - theophylline
EDAT- 2022/04/27 06:00
MHDA- 2022/08/25 06:00
CRDT- 2022/04/26 06:00
PHST- 2022/03/19 00:00 [revised]
PHST- 2022/02/19 00:00 [received]
PHST- 2022/03/30 00:00 [accepted]
PHST- 2022/04/27 06:00 [pubmed]
PHST- 2022/08/25 06:00 [medline]
PHST- 2022/04/26 06:00 [entrez]
AID - 10.1111/jcpt.13670 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2022 Aug;47(8):1264-1269. doi: 10.1111/jcpt.13670. Epub 2022 
      Apr 25.